267293

The Role of Serum Midkine and Secretory Leucocyte Protease Inhibitor in Diagnosis of Thyroid Cancer

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Introduction: The most frequent endocrine cancer is thyroid cancer. 95% of thyroid cancer cases are papillary thyroid carcinomas (PTC) and follicular thyroid carcinomas (FTC). Aim: The study aimed to assess the value of serum midkine and secretory leucocyte protease inhibitor as noninvasive diagnostic markers for thyroid cancer. Serum levels of these markers concerning different thyroid cancer stages were also studied. Patients and methods: This study included fifteen healthy controls with age and sex-matched thyroid cancer, and benign thyroid problem patients. Serum Midkine and secretory leucocyte protease inhibitor levels were measured by ELISA technique. Results: Individuals with thyroid cancer had considerably greater midkine levels than patients with benign thyroid disorders and the control group. The SLPI was significantly higher in thyroid cancer patients compared to the control group. it was found that midkine had 88.4% accuracy with the area under curve 0.95 at cutoff point 895 pg/ml while SLPI had 61.2% accuracy with the area under curve 0.64 at cutoff point 1275.5 ng/ml. Conclusion: Serum Midkine level and secretory leucocyte protease inhibitor are good markers for the detection of thyroid cancer with correlation with tumor stage.

DOI

10.21608/ejhm.2022.267293

Keywords

Thyroid nodule, biomarker, Thyroid Cancer, Midkine, secretory leucocyte protease inhibitor

Authors

First Name

Hanan G.

Last Name

Abdel-Azeem

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Amal M.

Last Name

Abdel-aal

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Mohamed H.

Last Name

Mahran

MiddleName

-

Affiliation

-

Email

-

City

-

Orcid

-

First Name

Marwa H.

Last Name

Thabet

MiddleName

-

Affiliation

-

Email

meromoro1010@gmail.com

City

-

Orcid

-

Volume

89

Article Issue

1

Related Issue

36332

Issue Date

2022-10-01

Receive Date

2022-10-27

Publish Date

2022-10-01

Page Start

6,039

Page End

6,035

Print ISSN

1687-2002

Online ISSN

2090-7125

Link

https://ejhm.journals.ekb.eg/article_267293.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=267293

Order

298

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

The Role of Serum Midkine and Secretory Leucocyte Protease Inhibitor in Diagnosis of Thyroid Cancer

Details

Type

Article

Created At

22 Jan 2023